Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds eukaryotic cell or component thereof or substance...
Reexamination Certificate
2007-07-26
2010-02-23
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds eukaryotic cell or component thereof or substance...
C424S130100, C424S141100, C424S158100, C424S172100
Reexamination Certificate
active
07666423
ABSTRACT:
The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and prevent tumor formation and progression and to inhibit tumor cell aggressiveness. The invention further provides methods of inhibiting tumor cell growth and/or treating aggressive tumors in a mammal comprising administering to the mammal, having at least one tumor cell present in its body, an effective amount of an inhibitor of Nodal activity.
REFERENCES:
patent: 5916751 (1999-06-01), Tabibzadeh et al.
patent: 6027917 (2000-02-01), Celeste et al.
patent: 6294330 (2001-09-01), Michnick et al.
patent: 6428966 (2002-08-01), Lee et al.
patent: 6472179 (2002-10-01), Stahl et al.
patent: 6492493 (2002-12-01), Celeste et al.
patent: 6635480 (2003-10-01), Lee et al.
patent: 6649588 (2003-11-01), Tabibzadeh et al.
patent: 6747004 (2004-06-01), Tabibzadeh
patent: 6878807 (2005-04-01), Desnoyers et al.
patent: 7074592 (2006-07-01), Ashkenazi et al.
patent: 7147853 (2006-12-01), Goddard et al.
patent: 7151086 (2006-12-01), Celeste et al.
patent: 7211644 (2007-05-01), Tabibzadeh
patent: 7270963 (2007-09-01), Lee et al.
patent: 7307152 (2007-12-01), Desnoyers et al.
patent: 2002/0086351 (2002-07-01), Ebner et al.
patent: 2003/0021792 (2003-01-01), Roben et al.
patent: 2003/0069408 (2003-04-01), Ebner et al.
patent: 2003/0224411 (2003-12-01), Stanton et al.
patent: 2004/0147045 (2004-07-01), Nelson
patent: 2004/0152885 (2004-08-01), Amegadzie et al.
patent: 2004/0180347 (2004-09-01), Stanton et al.
patent: 2004/0214324 (2004-10-01), Isacson et al.
patent: 2005/0144660 (2005-06-01), Mishra
patent: 2005/0208045 (2005-09-01), Vale et al.
patent: 2006/0099576 (2006-05-01), Tabibzadeh
patent: 2006/0134636 (2006-06-01), Stanton et al.
patent: 2007/0010012 (2007-01-01), Gold et al.
patent: 2007/0031823 (2007-02-01), Bentwich
patent: 2007/0042958 (2007-02-01), Knopf et al.
patent: 2007/0065415 (2007-03-01), Kleinsek et al.
patent: 2007/0077553 (2007-04-01), Bentwich
patent: 2007/0078101 (2007-04-01), Brivanlou et al.
patent: 2007/0105122 (2007-05-01), Ota et al.
patent: 2007/0155661 (2007-07-01), Kim
patent: 2007/0281355 (2007-12-01), Dalton et al.
Cochlovius et al., 2003, Modern Drug Discovery, vol. 6, No. 10, p. 33-34, 37-38.
Weiner et al., 2000, Oncogene, vol. 19, p. 6144-6151.
Postovit Lynne-Marie et al.: “A three-dimensional model to study the epigenetic effects induced by he microenvironment of human embryonic stem cells,” Stem Cells (Miamisburg), vol. 24, No. 3, Mar. 2006, pp. 501-505.
Minchiotti Gabriella: “Nodal-dependant Cripto signaling in ES cells: from stem cells to tumor biology,” Oncogene, vol. 24, No. 37, Aug. 2005, pp. 5668-5675.
Lee Lisa M.J. et al.: “The fate of human malignant melanoma cells transplanted into zebrafish embryos: Assessment of migration and cell division in the absence of tumor formation,” Developmental Dynamics, vol. 233, No. 4, Aug. 2005, pp. 1560-1570.
Kulesa Paul M. et al.: “Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, No. 10, Mar. 2006, pp. 3752-3757.
Topczewska Jolanta M. et al.: “Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness,” Nature Medicine, vol. 12, No. 8, Aug. 2006, pp. 925-932.
Hendrix Mary J. C. et al.: “Reprogramming metastatic tumor cells with embryonic microenvironments,” Nature Reviews Cancer, vol. 7, No. 4, Apr. 2007, pp. 246-255.
Strizz, et al., Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention, Expert Reviews Ltd., 2009, pp. 67-78.
Glennie, Martin J. and Johnson, Peter W.M., Clinical trials of antibody therapy, Immun. Today, vol. 21, No. 8, Aug. 2000, pp. 403-410.
Hendrix Mary Jessica
Postovit Lynne-Marie
Seftor Elisabeth Ann
Seftor Richard Edward Barnet
Chen Shin-Lin
Children's Memorial Hospital
Patton & Boggs LLP
LandOfFree
Methods of inhibiting tumor cell aggressiveness using the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting tumor cell aggressiveness using the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting tumor cell aggressiveness using the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4195678